BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 16985182)

  • 1. Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group.
    Bhatia S; Krailo MD; Chen Z; Burden L; Askin FB; Dickman PS; Grier HE; Link MP; Meyers PA; Perlman EJ; Rausen AR; Robison LL; Vietti TJ; Miser JS
    Blood; 2007 Jan; 109(1):46-51. PubMed ID: 16985182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second malignancies after ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study.
    Paulussen M; Ahrens S; Lehnert M; Taeger D; Hense HW; Wagner A; Dunst J; Harms D; Reiter A; Henze G; Niemeyer C; Göbel U; Kremens B; Fölsch UR; Aulitzky WE; Voûte PA; Zoubek A; Jürgens H
    Ann Oncol; 2001 Nov; 12(11):1619-30. PubMed ID: 11822764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.
    Grier HE; Krailo MD; Tarbell NJ; Link MP; Fryer CJ; Pritchard DJ; Gebhardt MC; Dickman PS; Perlman EJ; Meyers PA; Donaldson SS; Moore S; Rausen AR; Vietti TJ; Miser JS
    N Engl J Med; 2003 Feb; 348(8):694-701. PubMed ID: 12594313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study.
    Miser JS; Krailo MD; Tarbell NJ; Link MP; Fryer CJ; Pritchard DJ; Gebhardt MC; Dickman PS; Perlman EJ; Meyers PA; Donaldson SS; Moore S; Rausen AR; Vietti TJ; Grier HE
    J Clin Oncol; 2004 Jul; 22(14):2873-6. PubMed ID: 15254055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group.
    Womer RB; West DC; Krailo MD; Dickman PS; Pawel BR; Grier HE; Marcus K; Sailer S; Healey JH; Dormans JP; Weiss AR
    J Clin Oncol; 2012 Nov; 30(33):4148-54. PubMed ID: 23091096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study.
    Granowetter L; Womer R; Devidas M; Krailo M; Wang C; Bernstein M; Marina N; Leavey P; Gebhardt M; Healey J; Shamberger RC; Goorin A; Miser J; Meyer J; Arndt CA; Sailer S; Marcus K; Perlman E; Dickman P; Grier HE
    J Clin Oncol; 2009 May; 27(15):2536-41. PubMed ID: 19349548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial.
    Le Deley MC; Paulussen M; Lewis I; Brennan B; Ranft A; Whelan J; Le Teuff G; Michon J; Ladenstein R; Marec-Bérard P; van den Berg H; Hjorth L; Wheatley K; Judson I; Juergens H; Craft A; Oberlin O; Dirksen U
    J Clin Oncol; 2014 Aug; 32(23):2440-8. PubMed ID: 24982464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High histologic and overall response to dose intensification of ifosfamide, carboplatin, and etoposide with cyclophosphamide, doxorubicin, and vincristine in patients with high-risk Ewing sarcoma family tumors: the Bambino Gesù Children's Hospital experience.
    Milano GM; Cozza R; Ilari I; De Sio L; Boldrini R; Jenkner A; De Ioris M; Inserra A; Dominici C; Donfrancesco A
    Cancer; 2006 Apr; 106(8):1838-45. PubMed ID: 16532434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review.
    Kushner BH; Meyers PA
    J Clin Oncol; 2001 Feb; 19(3):870-80. PubMed ID: 11157041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy dose-intensification for pediatric patients with Ewing's family of tumors and desmoplastic small round-cell tumors: a feasibility study at St. Jude Children's Research Hospital.
    Marina NM; Pappo AS; Parham DM; Cain AM; Rao BN; Poquette CA; Pratt CB; Greenwald C; Meyer WH
    J Clin Oncol; 1999 Jan; 17(1):180-90. PubMed ID: 10458232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience.
    Navid F; Santana VM; Billups CA; Merchant TE; Furman WL; Spunt SL; Cain AM; Rao BN; Hale GA; Pappo AS
    Cancer; 2006 Apr; 106(8):1846-56. PubMed ID: 16541446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults.
    Kushner BH; Meyers PA; Gerald WL; Healey JH; La Quaglia MP; Boland P; Wollner N; Casper ES; Aledo A; Heller G
    J Clin Oncol; 1995 Nov; 13(11):2796-804. PubMed ID: 7595741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Local control in pelvic Ewing sarcoma: analysis from INT-0091--a report from the Children's Oncology Group.
    Yock TI; Krailo M; Fryer CJ; Donaldson SS; Miser JS; Chen Z; Bernstein M; Laurie F; Gebhardt MC; Grier HE; Tarbell NJ;
    J Clin Oncol; 2006 Aug; 24(24):3838-43. PubMed ID: 16921035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vincristine, doxorubicin, cyclophosfamide, actinomycin D, ifosfamide, and etoposide in adult and pediatric patients with nonmetastatic Ewing sarcoma. Final results of a monoinstitutional study.
    Ferrari S; Palmerini E; Alberghini M; Staals E; Mercuri M; Barbieri E; Longhi A; Cantero L; Cesari M; Abate M; Balladelli A; Picci P; Bacci G
    Tumori; 2010; 96(2):213-8. PubMed ID: 20572576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.
    Brennan B; Kirton L; Marec-Bérard P; Gaspar N; Laurence V; Martín-Broto J; Sastre A; Gelderblom H; Owens C; Fenwick N; Strauss S; Moroz V; Whelan J; Wheatley K
    Lancet; 2022 Oct; 400(10362):1513-1521. PubMed ID: 36522207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours - EURO EWING 2012 Protocol.
    Anderton J; Moroz V; Marec-Bérard P; Gaspar N; Laurence V; Martín-Broto J; Sastre A; Gelderblom H; Owens C; Kaiser S; Fernández-Pinto M; Fenwick N; Evans A; Strauss S; Whelan J; Wheatley K; Brennan B
    Trials; 2020 Jan; 21(1):96. PubMed ID: 31952545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose ifosfamide with mesna uroprotection in Ewing's sarcoma.
    Jürgens H; Exner U; Kühl J; Ritter J; Treuner J; Weinel P; Winkler K; Göbel U
    Cancer Chemother Pharmacol; 1989; 24 Suppl 1():S40-4. PubMed ID: 2503258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Late toxicity comparison of alkylating-based maintenance regimen with cyclophosphamide (VAC) vs ifosfamide (VAI) in Ewing sarcoma survivors treated in the randomized clinical trial Euro-EWING99-R1 in France.
    Corvest V; Marec-Bérard P; Lervat C; Pacquement H; Toulmonde M; Gentet JC; Laurence V; Cleirec M; Mansuy L; Bompas E; Castex MP; Taque S; Filhon B; Tabone MD; Verité C; Entz-Werle N; Saumet L; Guimard G; Pondrom M; Chevreau C; Flandrin J; Duranteau L; Rousset-Jablonski C; Brugières L; Jimenez M; Le Deley MC; Gaspar N; Fresneau B
    Int J Cancer; 2023 Apr; 152(8):1659-1667. PubMed ID: 36250317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second malignancies after treatment for Ewing's sarcoma: a report of the CESS-studies.
    Dunst J; Ahrens S; Paulussen M; Rübe C; Winkelmann W; Zoubek A; Harms D; Jürgens H
    Int J Radiat Oncol Biol Phys; 1998 Sep; 42(2):379-84. PubMed ID: 9788419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No advantages in the addition of ifosfamide and VP-16 to the standard four-drug regimen in the maintenance phase of neoadjuvant chemotherapy of Ewing's sarcoma of bone: results of two sequential studies.
    Bacci G; Picci P; Ruggieri P; Ferrari S; Mercuri M; Fabbri N; Rosito P; Barbieri E; Ferraro A; Casadei R
    J Chemother; 1993 Aug; 5(4):247-57. PubMed ID: 8229153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.